Prebiotic soda eased GI symptoms in adults on semaglutide or tirzepatide in a small open-label trial
In an 80-adult open-label pilot, a daily prebiotic soda cut GLP-1 stomach symptoms more than usual fluids over 4 weeks. Industry-linked and unblinded.
Summary
GLP-1 drugs like semaglutide and tirzepatide often cause constipation, abdominal pain and indigestion, which can hurt quality of life and lead people to stop treatment. This pilot trial randomized 80 adults with at least one GI symptom to drink a prebiotic soda (OLIPOP, one can a day, optionally two) for 4 weeks or to keep their usual fluids. Sixty-eight finished. The soda group's GI symptom score fell more than the control group's (difference -0.526 on the GSRS scale, 95% CI -0.713 to -0.339). Constipation, abdominal pain and indigestion improved most, and overall quality-of-life scores also favored the soda (p = 0.037). The trial was open-label, so participants knew their group, the control was not a matched beverage, and the study was short and small. Two authors work for the soda maker. The authors call the results preliminary and want larger blinded trials.
Detailed Summary
Gastrointestinal side effects are among the most common reasons people struggle with GLP-1-based weight-loss drugs. Constipation, abdominal pain and indigestion can erode quality of life and may lead people to stop treatment, which matters for anyone relying on these drugs for metabolic health and healthspan. Practical, low-risk ways to ease these symptoms are therefore of real interest.
This pilot tested one such approach. Researchers randomized 80 adults who had recently started semaglutide or tirzepatide and had at least one GI symptom. Half were asked to drink a prebiotic functional soda (OLIPOP) daily, one can with the option of two, for 4 weeks. The other half continued their usual fluid intake. The primary outcome was change in the Gastrointestinal Symptom Rating Scale (GSRS) total score. Secondary outcomes included GSRS subscales, SF-36 quality of life, stool characteristics, appetite, diet and rescue medication use.
Sixty-eight participants completed the study (36 soda, 32 control). The GSRS total score fell by 0.931 in the soda group versus 0.405 in controls, a between-group difference of -0.526 (95% CI -0.713 to -0.339; p < 0.001). Constipation, abdominal pain and indigestion showed greater reductions with the soda. Overall SF-36 scores also differed significantly (p = 0.037). The abstract does not report results for stool characteristics, appetite, cravings or rescue medication use, and it does not mention adverse events.
The findings suggest a prebiotic beverage may be a reasonable adjunct for GLP-1 GI discomfort, but this is a symptom-score result in a small pilot. The abstract does not describe a mechanism, such as fiber effects on stool or the microbiome, so none can be claimed here.
Caveats are substantial. The trial was open-label with a no-beverage control, so expectation effects and extra fluid intake could contribute to symptom reports that are self-rated. Two authors are employed by the soda's maker. The authors themselves call for larger blinded trials with a matched beverage control. This summary is based on the abstract only.
Key Findings
- Randomized open-label pilot: 80 adults on semaglutide or tirzepatide; 68 completed 4 weeks (36 soda, 32 control).
- GSRS total score fell more with prebiotic soda: -0.931 vs -0.405, difference -0.526 (95% CI -0.713 to -0.339).
- Constipation, abdominal pain and indigestion subscales improved more with soda than with usual fluids.
- SF-36 overall quality of life differed between groups (p = 0.037), a weaker signal than the primary outcome.
- Results are self-reported symptoms only; no blinding, no matched beverage control, and no mechanism or lifespan data were reported.
Methodology
Open-label, 1:1 randomized controlled pilot (NCT07744360) in 80 adults on semaglutide or tirzepatide with at least one GI symptom. The intervention was one can daily (optionally two) of OLIPOP for 4 weeks versus usual free-living fluid intake. The primary endpoint was change in GSRS total score, with secondary SF-36, stool, appetite, diet and rescue medication outcomes.
Study Limitations
This summary is based on the abstract only. The trial was open-label with no matched beverage control, 12 of 80 participants dropped out, follow-up was 4 weeks, outcomes were self-reported, and two authors are employed by the manufacturer. Details on adverse events, the secondary outcomes beyond those reported, and weight or persistence outcomes were not available in the abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
